Jasper Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Jasper Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2020 to 2023.
  • Jasper Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$18.6M, a 61.1% increase year-over-year.
  • Jasper Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$33.2M.
  • Jasper Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$64.5M, a 71.1% decline from 2022.
  • Jasper Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$37.7M, a 23% decline from 2021.
  • Jasper Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$30.6M, a 3.26% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$64.5M -$26.8M -71.1% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-05
2022 -$37.7M -$7.05M -23% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-05
2021 -$30.6M +$1.03M +3.26% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-08
2020 -$31.7M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.